NCBP2AS2 and COVID-19: Antisense lncRNAs, including A2M-AS1 (alpha-2-macroglobulin antisense RNA 1), DBH-AS1 (dopamine β hydroxylase antisense RNA 1), FLVCR1-DT (Feline Leukemia Virus Subgroup C Cellular Receptor 1- divergent transcript), NCBP2AS2 (nuclear cap-binding protein subunit-2 antisense RNA 2), and FLVCR1 (Feline Leukemia Virus Subgroup C Cellular Receptor 1) were enrolled in this study of COVID-19 patients to assess their roles in disease severity.